|
|
|
|
 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
[2013]
- 2012
- 2011
- 2010
- 2009
- 2008
- 2007
- 2006
- 2005
- 2004
- 2003
- 2002
(click to view the full text)
|
May 15, 2013
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto |
May 8, 2013
Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders |
May 7, 2013
Aeterna Zentaris Reports First Quarter 2013 Financial and Operating Results |
May 1, 2013
Aeterna Zentaris to Announce First Quarter 2013 Financial and Operating Results on May 7, 2013 and Hold Annual Shareholders Meeting on May 8, 2013 |
April 23, 2013
Aeterna Zentaris Newly Appointed CEO, David A. Dodd, to Host Introductory Analyst and Investor Conference Call on Thursday, April 25, 2013 |
April 17, 2013
Aeterna Zentaris Announces Transfer of Manufacturing Rights Related to Cetrotide® to Merck KGaA |
April 15, 2013
David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc. |
April 10, 2013
Aeterna Zentaris Presents Encouraging Updated Data on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at AACR Meeting |
April 10, 2013
Aeterna Zentaris and Ergomed Sign Co-Development and Profit Sharing Agreement for AEZS-108 in Endometrial Cancer |
April 3, 2013
Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual Meeting |
March 21, 2013
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2012 Financial
and Operating Results |
March 13, 2013
Aeterna Zentaris to Present at Upcoming Roth 25th Annual OC Growth Stock Conference |
March 12, 2013
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2012 Financial and Operating Results on March 21, 2013 |
March 11, 2013
Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine Following Data Safety Monitoring Board Recommendation |
February 20, 2013
Aeterna Zentaris: First Patient Treated for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer |
 |
 |
|
|
|
